# Enoxaparin Versus Dalteparin for Venous Thromboembolism Prophylaxis in Hip and Knee Arthroplasty: A Systematic Review

## TL;DR

This review compares enoxaparin and dalteparin for preventing blood clots after hip or knee surgery, finding similar effectiveness but possible safety and cost benefits with dalteparin.

## Contribution

A systematic review comparing enoxaparin and dalteparin for VTE prophylaxis in hip and knee arthroplasty, highlighting safety and cost differences.

## Key findings

- Enoxaparin and dalteparin show similar effectiveness in preventing VTE after hip or knee surgery.
- Dalteparin may be associated with fewer bleeding events and lower transfusion rates.
- One study reported potential cost savings with dalteparin.

## Abstract

Venous thromboembolism (VTE) is a serious postoperative complication in patients undergoing total hip or knee arthroplasty, with both pulmonary embolisms and deep vein thromboses being major causes of preventable morbidity and mortality. Low-molecular-weight heparins such as enoxaparin and dalteparin are widely used for thromboprophylaxis, but direct comparative data are limited. We aimed to do a systematic review of the literature to compare the efficacy and safety of enoxaparin and dalteparin in preventing VTE following total hip or knee replacement surgery. A systematic literature search was conducted in MEDLINE, PubMed, Embase, and the Cochrane Library. After deduplication, 145 studies were screened, 28 full texts were assessed, and three papers were included. Eligible studies were randomised controlled trials (RCTs) or observational studies comparing enoxaparin and dalteparin in adult patients undergoing hip or knee arthroplasty, reporting VTE rates as the primary outcome. Risk of bias (ROB) was assessed using the Cochrane RoB 2 tool for randomised trials and the Newcastle-Ottawa Scale for observational studies. Three studies - one RCT and two retrospective cohort studies with a total of 1,167 patients - met the inclusion criteria. Across all studies, VTE incidence was low with no significant difference between enoxaparin and dalteparin. Some evidence suggested dalteparin may be associated with fewer bleeding events and lower transfusion rates, with one study also reporting cost savings. ROB was moderate in the observational studies, with some concerns in the RCTs. Enoxaparin and dalteparin appear similarly effective for VTE prevention after hip or knee arthroplasty. However, dalteparin may be associated with a lower bleeding risk and reduced transfusion rates, with potential cost savings. Current evidence is limited by the small number and quality of studies. Further high-quality randomised trials are needed to confirm these findings and inform clinical decision-making.